Loading...
•
Jun 30
Merit Medical Q2 2025 Earnings Report
NewMarket reported steady Q2 2025 financial performance with flat net income and a modest revenue decline year-over-year.
Key Takeaways
NewMarket generated $698.5 million in revenue and $111.2 million in net income in Q2 2025. EPS increased slightly despite lower petroleum additives revenue and shipments. Strong performance in specialty materials offset some of the headwinds.
Q2 revenue declined slightly to $698.5 million from $710.2 million last year
Net income remained stable at $111.2 million with EPS of $11.84
Petroleum additives shipments fell 2.5% year-over-year
Specialty materials segment posted revenue growth and more than doubled operating profit
Merit Medical
Merit Medical
Merit Medical Revenue by Segment
Revenue by Segment
Petroleum Additives Revenue
CapyFin.comSpecialty Materials Revenue
CapyFin.comAll Other Revenue
CapyFin.com Forward Guidance
NewMarket did not issue specific financial projections but emphasized a long-term focus and strong operational discipline.
Positive Outlook
- Continued investment in technology and product mix
- Specialty materials momentum contributed to margin expansion
- Strong cash flow allowed for share repurchases and dividend payouts
- Net debt reduced by $122 million in first half
- Net Debt to EBITDA ratio improved to 1.0
Challenges Ahead
- No formal forward revenue or EPS guidance issued
- Petroleum additives revenue and shipments declined
- Higher R&D and SG&A expenses reduced overall margins
- Ongoing macroeconomic uncertainty and trade risks remain
- Decline in year-over-year total revenue
Revenue & Expenses
Visualization of income flow from segment revenue to net income